AI assistant
Aclaris Therapeutics, Inc. — Director's Dealing 2020
Jun 3, 2020
33670_dirs_2020-06-03_aecb06ab-bf0d-46a6-b308-3fe215c38723.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Aclaris Therapeutics, Inc. (ACRS)
CIK: 0001557746
Period of Report: 2020-06-01
Reporting Person: Walker Neal (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-06-01 | Common Stock | M | 73014 | — | Acquired | 1107907 | Direct |
| 2020-06-01 | Common Stock | F | 20976 | $1.32 | Disposed | 1086931 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-06-01 | Restricted stock units | $ | M | 73014 | Disposed | Common Stock (73014) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4.
F3: The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.